Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

BIO-MICRO: Biomarkers and Intervention Outcomes in Micronutrient Optimization

Project description

Training for personalised micronutrient deficiency treatment

Micronutrient (MN) deficiencies in critically ill patients can delay recovery. Current diagnostic methods are often inadequate, and care usually relies on fixed-dose treatments rather than personalised care. Customising MN therapy and researching their post-ICU roles could improve results. With the support of the Marie Skłodowska-Curie Actions programme, the BIO-MICRO project will train research fellows to develop strategies for personalised MN therapy in critically ill patients. It will focus on reliably determining MN status, identifying patient subphenotypes that may benefit from therapy, and optimising the timing of treatment. The project seeks to reduce mortality, organ dysfunction, and ICU stays while improving quality of life and lowering costs.

Objective

European micronutrient (MN) guidelines explicitly recommend to replete any MN deficiency in critically ill patients. MNs are crucial for immune defence, cellular metabolism and as antioxidant. Critically ill patients have increased requirements for MNs which can result in severe deficiencies and worse clinical outcomes. There are currently no accurate methods to diagnose MN deficiencies in critically ill patients. MN plasma concentrations are substantially affected by inflammation. MN concentrations in erythrocytes and leukocytes or new functional markers may better reflect real deficiencies. Furthermore, most intervention trials with high-dose MN monotherapy yielded mixed results on clinical outcomes. Due to the absence of accurate monitoring tools of MN body status, all patients received fixed high-dose MN monotherapy. Personalized MN therapy based on subphenotyping of patients and accurate estimation of individual metabolic demands in all phases of disease may yield better outcome than this one-size-fits-all strategy. In addition, more insight in the complex interplay between MNs and the role of MNs in post-ICU phase is necessary to guide future trials. BIO-MICRO consists of physicians, biologists, methodologists, trialists, health scientists, clinical chemists, patient representatives and industrial participants and aims to train innovative research fellows with interdisciplinary and intersectoral skills to develop the urgently needed strategies for MN personalized therapy in critically ill patients. They will develop new analytics for reliably determination MN body status, investigate subphenotypes of patients likely to benefit from MN therapy, enable guidance with appropriate timing of MN therapy, investigate the interplay between MNs and explore the role of MNs in the rehabilitation phase. This will ultimately lead to significantly decreased mortality and organ dysfunctions, shorter ICU stay, improvement of quality of life and significant cost reductions.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-DN-01

See all projects funded under this call

Coordinator

STICHTING AMSTERDAM UMC
Net EU contribution
€ 610 571,52
Total cost
No data

Participants (8)

Partners (5)